1/39
Comprehensive vocabulary review of oncology treatment guidelines, oncologic pathophysiological mechanisms, cytotoxic versus targeted agents, and specific oral antineoplastic medications across solid tumors and hematologic malignancies.
Cytotoxic Chemotherapy
Non-selective systemic treatments that target rapidly dividing cells by directly interfering with cell division via antimetabolites, topoisomerase inhibitors, or alkylating agents.
Cytostatic / Targeted Therapies
Therapies that inhibit cancer growth by interfering with specific molecular targets or genetic alterations (such as overexpressed or mutated molecules) involved in tumor progression.
Capecitabine
Xeloda®
oral pyrimidine analog antimetabolite prodrug of fluorouracil (5-FU)
breast, colorectal, and gastric cancers.
Dosed at 1,000 to 1,250 mg/m2 BID for 14 days on, 7 days off; contraindicated if CrCl<30 mL/min.
Palbociclib
Ibrance®
CDK4/6 inhibitor indicated for HR+/HER2- advanced or metastatic breast cancer.
125 mg PO once daily for 21 days on, 7 days off of a 28-day cycle
myelosuppression
with food.
Ribociclib
Kisqali®
CDK4/6 inhibitor for HR+/HER2- early or metastatic breast cancer
600 mg PO once daily for 21 days on, 7 days off
myelosuppression, hepatotoxicity, and QTc prolongation, requiring baseline ECG and LFTs.
Abemaciclib
Verzenio
continuous-dose CDK4/6 inhibitor for breast cancer
BID in combination with AI or 200 mg BID as monotherapy;
noted for a high incidence of diarrhea requiring prompt antidiarrheal initiation at the first loose stool.
Neratinib
Nerlynx®
oral HER2+ inhibitor; breast cancer
240 mg PO daily with food, associated with a 95% incidence of diarrhea requiring mandatory antidiarrheal prophylaxis unless utilizing a dose-escalation protocol.
Lapatinib
Tykerb®
oral dual tyrosine kinase inhibitor targeting HER2+ breast cancer
taken on an empty stomach
carries a BBW hepatotoxicity.
Tucatinib
Tukysa®
HER2 kinase inhibitor; breast cancer
300 mg PO twice daily in combination with trastuzumab and capecitabine
hand-foot syndrome, hepatotoxicity, and stomatitis.
Alpelisib
Piqray®
PI3K inhibitor indicated for PIK3CA-mutated, HR+/HER2- metastatic breast cancer
300 mg daily with food
carries substantial risk of hyperglycemia and may require prophylactic metformin.
Olaparib
Lynparza®
PARP inhibitor indicated for BRCA-mutated HER2- breast cancer and recurrent or advanced ovarian/fallopian/peritoneal cancers;
300 mg PO twice daily
risk of secondary MDS/AML.
Niraparib
Zejula®
PARP inhibitor used as maintenance in epithelial ovarian, fallopian tube, or primary peritoneal cancer;
baseline dose is individualized to 200 mg daily for patients <77 kg or platelets <150,000/mcL, or 300 mg daily if ≥77 kg and ≥150,000/mcL.
Osimertinib
Tagrisso®
3rd-generation oral EGFR TKI indicated for EGFR exon 19 deletions, exon 21 L858R mutations, and T790M resistance mutations; lung cancer
requires cardiac monitoring (LVEF assessment) and QTc monitoring.
Erlotinib
Tarceva®
EGFR TKI; lung cancer
taken on an empty stomach
requires avoiding PPIs and careful spacing with H2 blockers, and is subject to reduced plasma concentrations from tobacco smoking.
Afatinib
Gilotrif®
EGFR inhibitor for nonresistant EGFR metastatic mutations; lung cancer
taken on an empty stomach at 40 mg daily;
paronychia, rash, stomatitis, and pulmonary interstitial lung disease (ILD).
Alectinib
Alecensa®
2nd-generation ALK inhibitor
600 mg PO twice daily with food for ALK+ metastatic NSCLC;
photosensitivity, elevated creatine kinase (CK), edema, and bradycardia/electrolyte abnormalities.
Capmatinib
Tabrecta®
MET tyrosine kinase inhibitor indicated for metastatic NSCLC harboring mutations that lead to MET exon 14 skipping;
400 mg PO twice daily.
Sotorasib
Lumakras®
KRAS G12C inhibitor
locally advanced or metastatic KRAS G12C-mutated NSCLC after at least 1 prior systemic therapy;
interacts strongly with acid-reducing agents.
Adagrasib
Krazati®
KRAS G12C inhibitor; NSCLC
edema, QTc prolongation, hepatotoxicity, and gastrointestinal toxicity.
Dabrafenib and Trametinib Combination
Tafinlar + Mekinist
targeted combination of a BRAF inhibitor (Dabrafenib, 150 mg BID) and a MEK inhibitor (Trametinib, 2 mg daily) indicated for BRAF V600E/K-mutated metastatic melanoma and NSCLC;
prominent adverse effect is pyrexia.
Vismodegib
Erivedge®
Hedgehog signaling pathway inhibitor used for advanced basal cell carcinoma;
carries a BBW for embryo-fetal death or severe birth defects, requiring strict blood donation (24 months) and semen donation (3 months) restrictions.
Regorafenib
Stivarga®
multikinase and VEGF inhibitor dosed at 160 mg daily on days 1–21 of a 28-day cycle;
requires administration with a low-fat meal (<600 calories, <30% fat)
BBW severe/fatal hepatotoxicity.
Trifluridine / Tipiracil
Lonsurf®
nucleoside metabolic inhibitor combination for refractory metastatic colorectal cancer dosed at 35 mg/m2 based on trifluridine BID on days 1–5 and 8–12 of a 28-day cycle;
dose must be held if baseline ANC is <1,500/mm3 or platelets <75,000/mcL.
Apalutamide
Erleada®
second-generation androgen receptor inhibitor dosed at 240 mg daily for castration-sensitive or castration-resistant prostate cancer;
falls, bone fractures, hypertension, and seizures.
Darolutamide
Nubeqa®
androgen receptor antagonist dosed at 600 mg PO twice daily with food for nonmetastatic castration-resistant or metastatic hormone-sensitive prostate cancer;
exhibits lower central nervous system penetration, reducing seizure risk.
Abiraterone Acetate
Zytiga®
CYP17 inhibitor dosed at 1,000 mg PO daily on an empty stomach in combination with prednisone (5 mg BID) to prevent secondary mineralocorticoid excess (hypertension, hypokalemia, fluid retention).
Gleostine
Lomustine
lipophilic nitrosourea alkylating agent dosed at 130 mg/m2 PO once every 6 weeks for intracranial tumors;
BBW for delayed, dose-related, cumulative, and potentially fatal myelosuppression requiring at least a 6-week count nadir assessment.
Temozolomide
Temodar®
alkylating agent that crosses the blood-brain barrier, indicated for glioblastoma multiforme and anaplastic astrocytoma;
taken on an empty stomach or at bedtime to reduce nausea
billable under Medicare Part B.
Imatinib
Gleevec®
first-generation BCR-ABL tyrosine kinase inhibitor for Ph+ CML; dosed at 400 to 600 mg daily with food and a large glass of water to reduce gastrointestinal irritation
Ponatinib
Iclusig®
potent multi-targeted TKI effective against BCR-ABL with the gatekeeper T315I mutation;
BBW for arterial occlusion events, venous thromboembolism, heart failure, and hepatotoxicity.
Asciminib
Scemblix®
allosteric STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor indicated for Ph+ CML, including patients with the T315I mutation (dosed at 200 mg PO twice daily on an empty stomach).
Ibrutinib
Imbruvica®
irreversible Bruton's tyrosine kinase (BTK) inhibitor indicated for CLL (420 mg PO daily);
a. fibrillation, bleeding/bruising, and transient lymphocytosis.
Venetoclax
Venclexta®
BCL-2 inhibitor used in CLL and AML; requires a strict 5-week ramp-up dosing schedule (20 mg, 50 mg, 100 mg, 200 mg, to 400 mg daily) alongside hydration and allopurinol prophylaxis to mitigate high risk of Tumor Lysis Syndrome (TLS).
Gilteritinib
Xospata®
targeted FLT3 inhibitor dosed at 120 mg daily for relapsed/refractory AML with a FLT3 mutation;
BBW for differentiation syndrome.
Ivosidenib
Tibsovo®
isocitrate dehydrogenase-1 (IDH1) inhibitor dosed at 500 mg daily for IDH1-mutated AML;
BBW differentiation syndrome and causes QTc prolongation.
Immunomodulatory Drugs (IMiDs) REMS Requirements
Mandatory risk evaluation and mitigation strategies for
thalidomide
lenalidomide
pomalidomide
due to severe teratogenicity; limits prescriptions to a maximum 28-day supply with no refills and requires two forms of contraception.
Ixazomib
Ninlaro®
reversible proteasome inhibitor dosed at 4 mg on days 1, 8, and 15 of a 28-day cycle with lenalidomide and dexamethasone for multiple myeloma;
must be taken on an empty stomach.
Selinexor
Xpovio®
selective inhibitor of nuclear export (XPO1 inhibitor) indicated for relapsed/refractory multiple myeloma; requires intensive antiemetic prophylaxis (such as a 5-HT3 antagonist) due to severe nausea and anorexia.
Fedratinib
Inrebic®
selective JAK2 and FLT3 inhibitor for primary or secondary myelofibrosis (400 mg PO daily);
BBW for encephalopathy, including Wernicke's encephalopathy, requiring mandatory thiamine assessment and supplementation.
Ruxolitinib Phosphate
Jakafi®
JAK1 and JAK2 inhibitor indicated for myelofibrosis and polycythemia vera;
dosed based on baseline platelet count and requires gradual dose tapering upon discontinuation to prevent acute disease flare.